Highly rated in
Highly rated in
Check Dr. Priya S. Kishnani's experience treating your condition:
About Dr. Priya S. Kishnani

Priya Kishnani is a Pediatrics expert in Durham, North Carolina. Kishnani has been practicing medicine for over 36 years and is highly rated in 14 conditions, according to our data. Her top areas of expertise are Pompe Disease, Glycogen Storage Disease Type 3, Glycogen Storage Disease Type 9, and Hypophosphatasia (HPP). She is licensed to treat patients in North Carolina. Kishnani is currently accepting new patients.

Her clinical research consists of co-authoring 285 peer reviewed articles and participating in 19 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Priya S. Kishnani it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Priya S. Kishnani accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Cigna
  •  Aetna

Call to see if your plan is accepted.
3000 Erwin Rd, Durham, NC 27705
Background & Education
Graduate Institution
Other, 1987
Pediatrics in NC
Hospital Affiliations
Atrium Health Carolinas Medical Center
Duke University Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

GBE Deficiency (GSD IV and APBD) Natural History Study
Cognitive and Neurological Pathologies in Pompe Disease
GSD VI and GSD IX Natural History
A Long-term Follow-up Study of Gaucher Disease
Natural History Study of Adult and Pediatric Patients With Hypophosphatasia
Developing a Management Approach for Patients With Late-Onset Pompe Disease GAA Variant Identified by Newborn Screening
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A 20-Week Double-Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Rivastigmine in Children (Ages 10-18) With Down Syndrome
View 9 Less Clinical Trials -

285 Total Publications

In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors